Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor

Table 1 Characteristics of surgical cancer patients

	Well differentiated	Mediate differentiated	Poorly differentiated	P value
	(G1) (n = 4)	(G2) (n = 17)	(G3) (n = 10)
Age^†	57 (50–63)	59 (56–66)	58 (52–61)	ns
BMI^†	22.2 (20.0–28.6)	23.4 (20.3–25.0)	21.4 (20.7–23.6)	ns
FIGO Surgical Stage				ns
I	16 (66.7 %)	10 (58.8 %)	5 (50.0 %)
II	3 (12.5 %)	1 (5.9 %)	0 (0.0 %)
III	4 (16.7 %)	6 (35.3 %)	3 (30.0 %)
IV	1 (4.2 %)	0 (0 %)	2 (20.0 %)

^†Median (Interquartile Range). FIGO International Federation of Gynecology and Obstetrics

ISSN: 1471-2407